RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > FDA and Personalized Medicine

FDA and Personalized Medicine

Posted 01 March 2011 | By

Regulatory Focus recently interviewed three US Food and Drug Administration (FDA) officials about the agency's perspective on personalized medicine. Following are excerpts from the interview with Lawrence J. Lesko, PhD, director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research (CDER); Elizabeth Mansfield, PhD, director for personalized medicine, Center for Devices and Radiological Health (CDRH); and Vicki Seyfert-Margolis, PhD, senior advisor for science innovation and policy, Office of the Commissioner.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.